This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


AnGes MG, Inc.
【Field/Business】
Pharmaceutical/Drug Discovery


last update:2016/3/10
Profile

Delegates :
President & CEO, Ei Yamada


Incorporated :
December  17 , 1999

Paid in Capital :
15214 Million yen  

Employees :
64 人

Address :
4F, Saito Bio-Incubator 7-7-15, Saito-asagi, Ibaraki OSAKA
〒567-0085

TEL/FAX :
+81-3-5730-2630 / +81-3-5730-2635

URL:
http://www.anges-mg.com/en

Attachment :

Mission/Background :
AnGes MG is a biotech company founded in December 1999 as a spin-out of Osaka University. AnGes MG focuses on the development and commercialisation of gene-based medical products including gene therapy, nucleic acid medical products and therapeutic vaccines for intractable diseases with high unmet medical needs.

Technology & Business
AnGes MG is currently conducting 2 major proprietary development projects; HGF (Hepatocyte Growth Factor) Plasmid and NF-kB Decoy Oligonucleotide.

<HGF Plasmid>
HGF Plasmid (Plasmid DNA encoding HGF gene) is designed to provide treatment for diseases such as Peripheral Arterial Disease with its angiogenic function. Japanese Phase 3 study conducted in patients with Critical Limb Ischemia showed favorable efficacy and safety results. HGF Plasmid is currently being developed as treatment for 1) Critical Limb Ischemia and 2) Primary Lymphedema.

<NF-kB Decoy Oligonucleotide>
NF-kB Decoy Oligonucleotide is a specific inhibitor for NF-kB that acts as a switch to a gene cluster involved in the immune inflammatory response in the body. Research and development is performed to develop products for immune and inflammatory diseases.
Itis currently being developed as 1) Atopic Dermatitis ointment drug, 2) drug-coated balloon catheter to prevent restenosis, and 3) disc degeneration treatment.

Products & Service
Products & Service Name
Stage
Outline
Milestone
HGF Plasmid
Phase3
Target: Critical Limb Ischemia
NDA in Japan under conditional approval system
NF-kB Decoy Oligonucleotide
Phase3
Target: Atopic Dermatitis (moderate to severe atopic skin symptoms on face)
NDA in Japan
NF-kB Decoy Oligonucleotide
Preclinical
Target: Disc Degeneration
Start P1/2 study in the US








Highlights
-HGF Plasmid for Critical Limb Ischemia: Physician-led study in Japan
-NF-kB Decoy Oligonucleotide for Atopic Dermatitis: completed follow-up period in Japan Phase 3 study
-Drug-coated balloon catheter with NF-kB Decoy Oligonucleotide: completed follow-up period in the pivotal clinical study in Japan

Hot news

Alliance strategy
License-out: HGF Plasmid (excluding Critical Limb Ischemia in the US and Japan), NF-kB Decoy Oligonucleotide, and Hypertension DNA Vaccine


 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.